Report
Eli Lilly’s Zepbound–amylin combination led to significant weight loss in a mid-stage trial
STAT reports that high discontinuation rates in the study raised questions about the investigational therapy’s tolerability.
TLDR
STAT reports that Eli Lilly’s investigational combination of Zepbound and an amylin drug led to significant weight loss in a mid-stage trial, but high discontinuation rates raised questions about tolerability.
Combined views
7.3K
3 Sources, first seen ago